Skip to content

Investigation of the Radical Extent of lymphadenectomy of Laparoscopic Right Colectomy for Colon Cancer: a Randomized Controlled Trial

Investigation of the Radical Extent of lymphadenectomy of Laparoscopic Right Colectomy for Colon Cancer: a Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028591
Enrollment
Unknown
Registered
2019-12-28
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Right-sided olon cancer

Interventions

1:Procedure: Right Hemicolectomy with D2 lymph node dissection
2:Procedure: Right Hemicolectomy with D3 lymph node dissection

Sponsors

Renji Hospital, affiliated with the Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 = 4.0 x 10^9/L, PLT >= 100 x 10^9/L, AST & ALT < 2.5 times the maximum, TBIL < 1.5 times the maximum, INR < 1.5, liver function: Child A or B; 7. CT and Enhanced CT of chest, abdomen and pelvic: 1) envaluate stage of tumor: T2-T4N0T any N+; 2) eliminate any distant metastases; 8. ASA score: I-II; 9. ECOG score: 0-1; 10. agreement of the patient to participate in trial.

Exclusion criteria

Exclusion criteria: 1. patients combined with severe intestinal obstruction, perforation, etc. requiring emergency surgery; 2. not suitable for Laparoscopic surgeries (e.g. extensive adhesion from former abdominal surgeries; not suitable for pneumoperitoneum for any reason); 3. intraoperative exploration results: 1) the tumor has invaded surrounding organs and needs multivisceral resection; 2) distant metastases exist; 3) no possibilities for R0 resection; 4. women during Pregnancy or breast feeding period; 5. people with serious psychopathic diseases; 6. people unable to tolerate operation with serious emphysema, interstitial pneumonia, ischemic heart disease, etc.; 7. people in continous systemic steroids therapies in 1 month; 8. the patient or family menbers are not able to understand the conditions and target of the research.

Design outcomes

Primary

MeasureTime frame
3-year disease-free survival;

Secondary

MeasureTime frame
postoperative complication occurrence rate and mortality rate;3-year overall survival;3-year locoregional recurrence rate and distant metastasis rate;central lymph node metastasis rate;

Countries

China

Contacts

Public ContactYu Minhao

Renji Hospital, affiliated with the Shanghai Jiaotong University School of Medicine

fishmeangood@163.com+86 13661594237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026